2Yin WH, Chen JW, Jen HL, et al. Independent prognostk value of elevate dhigh -sensitivity C-reactive protein in chronic heart failure [J]. Am Heart J, 2004,147(5) :931-938.
3Neuhold S, Huelsmann M, Strunk G, et al. Comparison ofcopeptin, B-type natfiuretic peptide, and amino-terminalpro-B-type natriuretic peptide in patients with chronicheart failure:prediction of death at different stages of thedisease[ J]. J Am Coll Cardiol, 2008,52(4) : 266-272.
4Kelly D, Squire IB, Khan SQ, et al. C-terminal provaso-pressin (copeptin) is associated with left ventrieular dys-funetion, remodeling, and clinical heart failure in survivors of myocardial infarction [J]. J Card Fail, 2008,14(9) :739-745.
5Yamada T, Node K, Mine T, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: aprospactive randomized controlled study[ J]. Am Heart J, 2007,153(6) :128.
6Ahmed A. DEFEAT Heart Failure:a guide to management of geriat- ric heart failure by generalist physicians[J]. Minerva Med,2009, 100(1) :39 -50.
7Charloux A, Brandenberger G, Piquard F, et al. Dysregulation of p- ulsatility in aging IV. pulsatile signaling and cardiovascular aging: functions and regulation of natriuretic peptide signaling[J]. Ageing Res Rev,2008,7(3) :151 -163.
8Foteinos G, Hu Y, Xiao Q, et al. Rapid endothelial turnover in ather-osclerosis-prone areas coincides with stem cell repair in apollpopro- tein E-deficient mice [ J ]. Circulation,2008,117 (14) : 1856 - 1863.
